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ABSTRACT
Olfactory dysfunction is present in up to 90% of Alzheimer’s disease (AD) 
patients. Although deposition of hyperphosphorylated tau and β-amyloid substrates are 
present in olfactory areas, the molecular mechanisms associated with decreased smell 
function are not completely understood. We have applied mass spectrometry-based 
quantitative proteomics to probe additional molecular disturbances in postmortem 
olfactory bulbs (OB) dissected from AD cases respect to neurologically intact controls 
(n=20, mean age 82.1 years). Relative proteome abundance measurements have 
revealed protein interaction networks progressively disturbed across AD stages 
suggesting an early imbalance in splicing factors, subsequent interrupted cycling 
of neurotransmitters, alteration in toxic and protective mechanisms of β-amyloid, 
and finally, a mitochondrial dysfunction together with disturbance in neuron-neuron 
adhesion. We also present novel molecular findings in the OB in an autopsy cohort 
composed by Lewy body disease (LBD), frontotemporal lobar degeneration (FTLD), 
mixed dementia, and progressive supranuclear palsy (PSP) cases (n = 41, mean age 
79.7 years). Olfactory mediators deregulated during the progression of AD such as 
Visinin-like protein 1, RUFY3 protein, and Copine 6 were also differentially modulated 
in the OB in LBD, FTLD, and mixed dementia. Only Dipeptidyl aminopeptidase-like 
protein 6 showed a specific down-regulation in AD. However, no differences were 
observed in the olfactory expression of this protein panel in PSP subjects. This study 
demonstrates an olfactory progressive proteome modulation in AD, unveiling cross-
disease similarities and differences especially for specific proteins involved in dendritic 
and axonic distributions that occur in the OB during the neurodegenerative process.
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INTRODUCTION
The olfactory bulb (OB) is the first site for the 
processing of olfactory information in the brain and 
its deregulation is associated with neurodegenerative 
disorders (NDs) [1, 2]. In many cases, the olfactory 
deficit is an early event of these diseases being 
considered as a premotor sign of neurodegeneration and 
consequently, a reliable premature marker of NDs [3]. It 
has been suggested that the potential origins of olfactory 
dysfunction may be the depositions and inclusions of Tau, 
β-amyloid, and α-synuclein proteins in the OB, olfactory 
tract, and olfactory cortex [2, 4, 5]. Moreover, the presence 
and severity of hyperphosphorylated Tau, β-amyloid, and 
α-synuclein pathology in the OB reflects the presence and 
severity of respective pathologies in other brain regions 
[1]. On the other hand, the reduction of the cholinergic 
centrifugal inputs to the OB and the increased number of 
the dopaminergic cells observed in the OB region [4, 6] 
have also been suggested as potential origins of smell loss. 
Although olfactory involvement may also appear 
in healthy non-demented elderly subjects [7], olfactory 
dysfunction is present in up to 90% of AD patients [1]. 
Some studies suggest that olfactory dysfunction is an 
early event of AD, preceding the appearance of typical 
AD symptoms, such as memory loss, and dementia. 
Neuropathological studies have pointed out that olfactory 
centres are involved in early Braak stages [8], and OB 
pathology correlates with cortical AD pathology [2, 9, 10]. 
An OB atrophy and a significant reduction in olfactory 
performance have been detected in AD respect to control 
subjects using MRI and PET technologies [11, 12]. In view 
of these data, an in depth biochemical characterization of 
the neurodegeneration that occurs in the OB is mandatory 
as a first step for understanding early smell impairment 
in AD. 
For several decades, neuroanatomical, volumetric, 
and histological approaches have been the gold standard 
techniques employed to characterize the OB functionality. 
However, little attention has been focused specifically on 
the molecular composition of the OB from the perspective 
of proteomics [13-15]. We consider that deciphering the 
progressive proteome-wide alterations that occurs in the 
OB derived from AD cases with different Braak staging, 
might help develop early diagnosis and identify potential 
therapeutic targets for AD. 
In this study, we used mass-spectrometry based 
quantitative proteomics as a discovery platform in order 
to increase our knowledge about the patho-physiological 
mechanisms that are disturbed during the AD 
neurodegeneration in the OB. More than 200 differential 
proteins between controls and AD-related phenotype 
were detected, pinpointing specific pathways, protein 
interaction networks, and potential novel therapeutic 
targets that are modulated in specific Braak stages. Protein 
targets mainly involved in dendritic morphogenesis, 
neuronal injury and axonic distribution were evaluated 
in a cross-disease study, revealing common and distinct 
molecular perturbations between different Alzheimer-
related co-pathologies, providing novel candidate proteins 
for a druggability assessment at the level of the OB. 
RESULTS
In the present study, we have performed 
immunohistochemical analysis of β-amyloid and 
phosphorylated Tau in our OB sample collection derived 
from AD subjects (Table 1). The detection of β-amyloid 
was absent in nonpathological cases and increased along 
the progress of the disease. The morphology of the 
deposit was predominantly, in form of mature plaques in 
advanced stages, while in initial and intermediate stages, 
predominate the diffuse type of deposit. There was no 
specific anatomical localization of Aβ-protein in the OB 
(Figure 1). The detection of phospho-Tau protein was 
observed in all AD stages in form of neuropil threads and 
neurofibrillary tangles. The deposit was observed along 
the different layers of the OB. The intensity of phospho-
Tau deposit was increased in the anterior olfactory 
nucleus (AON) of advanced stages of AD compared to 
initial stages and control cases where AON phospho-
Tau staining was negative. In the OB of healthy patients 
there was only some isolated deposit of phospho-Tau 
protein (Figure 1). Although some variability in intensity 
and anatomical localization of protein aggregation were 
observed between different stages, our data allowed us to 
confirm the presence of neuropathological proteins in the 
OB from subjects with different Braak stages, reinforcing 
the involvement of the OB in pre-clinical stages of AD.
Large-scale identification of human olfactory bulb 
proteins by mass spectrometry
For shotgun proteomics experiments, we have used 
autopsy specimens of the right OB structure from AD 
cases and controls with no known neurological history 
(Table 1) with the final goal to obtain a profound insight 
into the protein content and protein function of the OB 
during the progression of AD. To screen the potential 
differences in OB protein expression profiles, OB 
specimens for each experimental group were separately 
subjected into isobaric tags (iTRAQ) coupled to 2D 
nano-liquid chromatography tandem mass spectrometry. 
Theoretically, pooling samples with a well characterized 
common pathologic phenotype, reduces the potential for 
aberrations in inter-sample, or biological variation. This 
reduction can improve the capacity to identify the most 
significant and consistent changes between stages. MS/
MS data from OB structure were processed to identify 
peptides that gave rise to observed spectra, and proteins 
were inferred based on identified peptides. Using this 
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workflow, we have generated an OB reference proteome 
map of 4,531 unique proteins identified with at least two 
peptides with ≥ 95% confidence (FDR lower than 1%). 
Complete lists of identifications and their corresponding 
scores are presented in Online Resources 2-3. To extract 
biological knowledge, the integrated OB proteome 
dataset was functionally categorized based on several 
pathway databases (online Resource 4). Although each 
bioinformatics platform produced diverse results, they 
commonly point out that tricarboxylic acid cycle, ubiquitin 
proteasome pathway and energy-releasing pathways are 
the general over-represented processes in OB as might be 
expected given the high metabolic demands of neurons 
(Online Resource 4). In order to gain a more detailed 
description of specific-neuronal pathways detected in the 
OB, subsequent analyses were performed to explore the 
proteome distribution across specific reactions using the 
PANTHER classification system [16]. Some statistically 
over-represented processes were directly relevant to 
synaptic vesicle trafficking, integrin signaling pathway, 
and histamine, dopamine, metabotropic glutamate and 
muscarinic acetylcholine receptor pathways (Online 
Resource 1-Figure 2, and Online Resource 4).
OB proteome dynamics during the AD 
progression
To further understand the OB molecular background 
contributing to the progression of AD, we have performed 
a differential OB proteome analysis in order to detect 
early and stage-dependent molecular events underlying 
the progression of AD. As expected, we have detected a 
substantial heterogeneity within the same Braak staging. 
This may be due to unpredictable confounders such as 
clinical, environmental, behavioral and agonal factors 
(i.e medication, substance abuse and health status prior 
to death) [17]. Among the 4531 identified proteins, 231 
proteins tend to be differentially expressed between 
controls and AD phenotypes (See Online Resource 
1-Figure 3, and Online Resource 5 and 6). In order to gain 
a more detailed description of the molecular mechanisms 
involved in the OB during AD progression, subsequent 
analyses were performed to explore the differential 
olfactory proteome distributions across specific pathways 
(Online Resource 6). As shown in Figure 2, our results 
point out a stage-dependent deregulation of specific 
pathways. Protein clusters involved in DNA repair and 
biological oxidations were specifically mapped in initial 
stages while protein groups involved in cell cycle, and 
signaling by insulin receptor, Rho GTPases, and GPCR 
Table 1: Subjects included in the proteomic discovery phase. 
The neuropathological assessment was performed according to Thal phases, CERAD score, NIA-AA guidelines and PART 
criteria [80-83]. βA immunopositivity was scored on a 4-tiered scale as: (-) negative, (+) 1-2 isolated βA depositions, (++) 
3-4 βA depositions, and (+++) >4 βA depositions. Graduation of phospho-TAU deposit: (-) negative +: low; ++: intermediate; 
+++ high. PMI: post-mortem interval; n.d: not determined; MP: Mature plaques; DP: Diffuse plaques (See neuropathological 
study section).
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were exclusively detected in intermediate stages. In 
advanced stages, specific protein mediators of metabolism 
of nucleotides and opioid signaling were de-regulated 
(Online Resource 6). On the other hand, a de-regulation in 
protein clusters related to axon guidance, and signaling by 
PDGF, NGF, and EGFR appears throughout intermediate 
and advanced stages. Interestingly, a cumulative proteome 
disturbance is detected in energy-integrating and diabetes 
pathways during the AD progression at the level of the 
OB, suggesting novel experimental pieces of evidence that 
link diabetes with dementia [18].
To enhance the analytical outcome of proteomic 
experiments, we have performed proteome-scale 
interaction networks merging the olfactory proteins 
that tend to be de-regulated across stages of AD. Using 
STRING software, a protein interactome map has 
been constructed for each stage. In initial stages, the 
heterogeneous nuclear ribonucleoprotein system was 
Figure 1: Representative immunohistochemical analysis of Beta-amyloid and p-Tau in OB. Negative Beta-amyloid staining 
in control A. and initial stage B. moderate staining in intermediate stage C. and abundant deposit in form of diffuse and mature plaques in 
advanced stage D. Sparse neuropil p-Tau threats in OB glomerular layer in a control case E. p-Tau deposit in external layer of OB (initial 
stage) F. p-Tau threats and tangles in anterior olfactory nucleus (intermediate stage) G. and abundant deposit of p-Tau in anterior olfactory 
nucleus (advanced stage) H. (all images are 20X).
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Figure 2: Differential olfactory proteome distributions across specific pathways. Using Reactome database, differential OB 
proteome across AD stages was mapped into regulatory pathways (See Online Resource 6 for more details).
Figure 3: Protein interactome map for differentially expressed proteins in initial stages. STRING analysis of known and 
predicted protein-protein interactions of gene-products differentially expressed in Braak stages I-II. STRING Version 9.1 and STRINGdb 
were used. Green circles: down-regulated proteins; red circles: up-regulated proteins.
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compromised in OB (alteration in HNRNPs; subnetwork 
A) (Figure 3), whereas a deregulation in protein 
composition of V-type proton ATPase (subnetwork B), 
collagen (up-regulation of COL6, COL14, COL18; 
subnetwork C), 14-3-3 complexes (down-regulation of 
YWHA proteins; subnetwork D), and a disturbance in 
neuron-neuron adhesion (L1CAM, NCAM1, ALCAM, 
NCAN, BCAN; subnetwork E) appears in intermediate 
stages (Figure 4). In advanced stages, alterations in 
mitochondrial complex I (NDUFs), complex II (SDHB), 
complex III (UQCRC2), and complex V (ATP5) suggest an 
impaired mitochondrial function (subnetwork G) (Figure 
5). Moreover, an imbalance in the neurotransmitter cycling 
(ATP6Vs, AP-1, AP-2; subnetwork F), and a disturbance 
in neuron-neuron adhesion and neurite growth (L1CAM, 
NCAM1, ALCAM, NCAN, BCAN; subnetwork E) also 
appear in advanced stages (Figure 5). 
Proteome-specific changes across AD staging
A total of 25 OB proteins were significantly 
differentially expressed proteins in specific stages (Table 
2 and Online Resource 1-Figure 4). We compared these 
results with previous published data on protein differential 
abundance in AD generated by similar proteomic 
workflows. Out of 25 proteins, 10 were mentioned as 
differentially abundant in CSF, cortex, or hippocampus 
derived from AD subjects [19-24] (Table 2 and Online 
Resource 5). We investigate whether some differential 
olfactory proteins are locally modified at the first stages 
of AD-related pathology when morphological lesions are 
restricted to the entorhinal and transentorhinal cortices of 
Figure 4: Protein interactome map for differentially expressed proteins in intermediate stages. STRING analysis of 
known and predicted protein-protein interactions of gene-products differentially expressed in Braak stages III-IV. STRING Version 9.1 and 
STRINGdb were used. Green circles: down-regulated proteins; red circles: up-regulated proteins.
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neurofibrillary pathology (Braak I-II). For that, Copine-6 
(CPNE6), Visinin-like protein 1 (VILIP1), Dipeptidyl 
aminopeptidase-like protein 6 (DPP6), and RUFY3 
protein (RIPX) were further analyzed. To our knowledge, 
CPNE6, DPP6, and RIPX have not previously been 
associated with the pathogenesis and progression of 
AD. However, VILIP1 is a secretable calcium-mediated 
neuronal injury marker with potential diagnostic utility for 
early AD [25, 26]. Independent of its role as an auxiliary 
subunit of Kv4-mediated A-type K (+) channels [27], 
DPP6 participates in the dendritic morphogenesis during 
the neuronal development in the hippocampus [28]. RIPX 
is a poorly characterized protein involved in the formation 
of a single axon by developing neurons [29]. CPNE6 has 
been described as a protein regulator of axon maturation 
in the olfactory tract [30]. As shown in Figure 4 and 5, 
subnetwork C showed a de-regulation of Collagen VI 
chains in intermediate/advanced stages. Some studies 
have demonstrated that collagen VI protects neurons 
against β-amyloid toxicity [31]. Using FpClass tool as a 
data mining-based method for proteome-wide protein-
protein interaction (PPI) predictions (http://dcv.uhnres.
Figure 5: Protein interactome map for differentially expressed proteins in advanced stages. STRING analysis of known and 
predicted protein-protein interactions of gene-products differentially expressed in Braak stages V-VI. STRING Version 9.1 and STRINGdb 
were used. Green circles: down-regulated proteins; red circles: up-regulated proteins. 
Oncotarget39444www.impactjournals.com/oncotarget
utoronto.ca/FPCLASS/) [32], we showed that AKAP12 
protein (Src-suppressed protein kinase C substrate) is a 
putative interactor of Collagen VI chains. This protein 
increases tau phosphorylation and promotes β-amyloid 
toxicity in neuron-like cells [33]. First, we performed 
immunohistochemical analysis to localize these proteins 
in the OB region. As shown in Figure 6, RIPX tends to be 
expressed and preferentially distributed in the glomerular 
and mitral layers of the OB (Figure 6A). However, 
CPNE6 is highly expressed by granular and mitral cell 
layers. In some AD cases, we detected a focal deposit 
in glomerular structures (Figure 6B). VILIP1 staining is 
diffuse in glomerular layer presenting focal protein deposit 
in some areas (Figure 6C). On the other hand, DPP6 is 
basically detected across neuropil in granular and mitral 
cell layers, presenting in some cases negative staining in 
the glomerular layer (Figure 6D). In the case of AKAP12, 
positive staining was detected at dendritic connections in 
glomerular layer (Figure 6E). In some AD cases, AKAP12 
expression was also detected in endothelial cells (Figure 
6E).
Despite the fact that inter-individual variability 
generally is muted by pooling strategy, validation of 
individual cases using downstream assays is needed. With 
the aim to complement and partially validate the iTRAQ-
based LC-MS/MS analysis, subsequent experiments 
were performed in order to check the steady-state levels 
of these proteins in individual cases by Western blotting. 
In accordance with our proteomic findings, olfactory 
VILIP1 was transiently up-regulated between early and 
intermediate stages respect to neurologically intact controls 
(Figure 7). In order to complement the tendency to DPP6 
down-regulation in AD phenotypes detected by proteomics 
(Table 2), Western blot analysis were performed across 
AD stages. As shown in Figure 7, statistically significant 
differences were detected in olfactory DPP6 protein levels 
in advanced stages. These data suggest that the dendritic 
morphology and the number of functional synapses in 
OB neurons may be compromised in advanced stages 
of the disease [28]. As shown in Figure 7, RIPX was 
significantly over-expressed in the OB across early and 
advanced AD stages compare to controls, suggesting 
that RIPX overexpression may enhance the axon length, 
reducing the percentage of olfactory neurons with multiple 
axons in AD [29]. As shown in Figure 7, AKAP12 protein 
expression was significantly increased in early stages of 
AD compared to controls. However, AKAP12 tend to be 
down-regulated in intermediate stages. These findings 
reinforce the idea that transient increase in AKAP12 and 
collagen VI protein levels may be part of the protective 
mechanisms against β-amyloid in olfactory neurons of AD 
patients [31, 33]. Our proteomic analysis revealed a down-
regulation of CPNE6 expression in a subset of patients 
across AD phenotypes (Supp table 5). In contrast, Western 
blot analysis revealed a tendency to down-regulation in 
early AD stages but no significant differences between 
AD phenotypes and controls was clearly detected (Figure 
6). The divergence observed between mass spectrometry 
and Western blot data may be due to a possible biased 
quantification in our pooling strategy [34]. Overall, a 
consistent trend was observed with proteomics results for 
the selected proteins with the exception of CPNE6.
Table 2: Top proteins significantly differentially expressed in specific AD stages. 
CB, CA (control group A and B), Initial Stage (A and B), Intermediate Stage (A and B), and Advanced Stage (A and B) 
correspond to the iTRAQ experimental design (see Online Resource 1-figure 1). Ratio corresponds to the protein reporter ion 
intensity originating from control group B (tag114), Initial stage group A (tag115), Initial stage group B (tag116), Intermediate 
Stage group A (tag117), Intermediate Stage group B (tag118), Advanced Stage group A (tag119), Advanced Stage group B 
(Tag121) relative to control group A (tag113). Proteins were considered to show a significant downward (green) or upward 
(red) trend if their expression ratios were < 0.77 or >1.3 respectively. Proteins mentioned in previous reports as differentially 
abundant in cortex, or hippocampus derived from AD subjects are indicated.
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OB protein expression of CPNE6, VILIP1, DPP6, 
and RIPX across Alzheimer-related co-pathologies
In contrast to the common separate investigation 
of NDs, targeted cross-disease studies comparing 
shared molecular relationships may give new insights 
into possible olfactory perturbations common for all or 
some NDs. In order to detect novel protein mediators 
shared by different Alzheimer-related co-pathologies at 
the level of the OB, we have evaluated the OB protein 
expression of CPNE6, VILIP1, DPP6, and RIPX by 
Figure 6: Immunohistochemical localization of AKAP12, RIPX, CPNE6, VILIP1, and DPP6 in human OB. A. 
Representative immunohistochemical staining pattern of RIPX. Non-pathological OB (left), AD OB (advanced stage) (middle) (4-10X). 
Detail of RIPX expression in the cytoplasm and axons of mitral cells (40X) (right). B. Representative immunohistochemical staining pattern 
of CPNE6. Non-pathological OB (left), AD OB (initial stage) (middle) (4-10X). Detail of intense nuclear CPNE6 expression and neuropil 
deposit in granular cell layer (20X) (right). C. Representative immunohistochemical staining pattern of VILIP1. Non-pathological OB 
(left), AD OB (Advanced stage) (middle) (10X). Detail of diffuse expression of VILIP1 across neuropil in anterior olfactory nucleus (40X) 
(right). D. Representative immunohistochemical staining pattern of DPP6. Non-pathological OB (left), AD OB (advanced stages) (middle) 
(4-20X). Detail of DPP6 expression in granular cells. No evidence of nuclear and cytoplasm deposit (20X) (right). E. Representative 
immunohistochemical staining pattern of AKAP12. Non-pathological OB (left), AD OB (Advanced stage) (middle) (10X). Detail of 
AKAP12 expression in dendritic connections in glomerular cell layer (40X).
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Western-blot across several AD-related diseases (n = 
41 OB samples). We have included pathologies with 
common smell impairment like LBD, and FTLD [1], PSP 
where olfactory loss occurs to a lesser extent or is absent 
[1, 35, 36], and mixed dementia (Mix AD VD). Mixed 
dementia is a condition in which Alzheimer’s disease 
and vascular dementia occur at the same time, and both 
separate disorders often display olfactory dysfunction 
[37, 38]. As shown in Figure 8, expression levels of our 
protein panel remained unchanged in the OB from PSP 
subjects respect to controls. Interestingly, although a 
tendency to DPP6 down-regulation is observed in FTLD 
and mixed dementia, a significant differential expression 
is not detected across NDs, suggesting that the alteration 
of olfactory protein expression of DPP6 tend to be 
specific for AD (Figure 8). In contrast, RIPX levels are 
significantly decreased in the OB from LBD, FTLD, 
and mixed dementia respect to protein levels detected in 
neurologically intact controls (Figure 8), whereas CPNE6 
levels is differentially down-regulated in the OB from 
LBD and mixed dementia (Figure 8). On the other hand, 
olfactory VILIP1 expression is significantly up-regulated 
in FTLD, and mixed dementia. As equivalent olfactory 
deficits are observed across NDs, our data suggest that 
specific shared pathways including common pathological 
substrates are disturbed during the OB neurodegeneration 
in some Alzheimer-related co-pathologies.
DISCUSSION
In view of the involvement of the olfactory 
dysfunction in AD, we consider that a quantitative 
knowledge of the olfactory neuroproteome across AD 
staging may help to understand the early smell impairment 
that occurs in this disease. The immunohistochemical 
study of β-amyloid and phospho-Tau allowed us to confirm 
the presence of neuropathological proteins in the OB of 
Figure 7: Olfactory bulb protein expression of AKAP12, CPNE6, VILIP1, DPP6, and RIPX across AD staging. Protein 
expression were documented by Western blot analyses with antibodies against the respective proteins. Upper panel displays representative 
Western blot gels (n = 2/experimental group) to detect AKAP12, CPNE6, VILIP1, DPP6, and RIPX protein levels in the OB during the AD 
progression. Lower panel shows histograms of band densities. Data are presented as mean ± SEM from five independent OB samples per 
group. *P < 0.05 vs control group; **P < 0.01 vs control group.
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subjects with distinct stages of AD progression, confirming 
the involvement of OB in pre-clinical stages of the disease 
[1]. Although it is widely believed that OB perturbations 
are responsible for olfactory dysfunction in NDs [1], few 
studies have examined this area using high throughput 
molecular technologies. Although transcriptomic analysis 
have revealed multiple metabolic alterations in the 
OB of a rat AD model [39], the temporal progression 
of the disease in murine models does not correlate 
well with human AD [40]. Different neuroproteomic 
studies have been attempted to discover novel protein 
mediators associated with AD pathogenesis in brain areas 
differentially affected by the disease [41-44]. However, 
to our knowledge, this is the first study to characterize 
potential AD-associated molecular changes in the OB 
using MS-based quantitative proteomics. Basically, the 
discovery strategy used was based on differential labeling 
of peptides using isobaric tags prior to their separation 
and analysis by multidimensional LC coupled to MS [45], 
revealing new insights into the OB site-specific proteomic 
signature during the progression of AD. More than 4,500 
proteins have been identified in human OB, being one of 
the most extensive proteomic characterization of a human 
brain area [46]. 231 proteins were significantly altered 
between some AD phenotypes and neurologically intact 
controls, where 11 potential biomarkers identified in 
the OB region (Serum albumin, 14-3-3 protein epsilon, 
Isoform 3 of Inter-alpha-trypsin inhibitor heavy chain 
H4, Antithrombin-III, Hemopexin, C4b-binding protein 
alpha chain, Gamma enolase, Phosphatidylethanolamine 
binding protein 1, Glial fibrillary acidic protein, Neuronal 
pentraxin-1, and Neurofascin) (see Online Resource 5) 
have already been proposed for their potential usefulness 
in AD diagnosis [23, 24, 47]. Interestingly, we have 
detected a down-regulation of specific HSP70 protein 
in OB from AD subjects (see Table 2). Intranasally-
Figure 8: Olfactory expression of CPNE6, VILIP1, DPP6, and RIPX proteins across Alzheimer-related co-pathologies. 
(Upper panel) Representative Western blot gels (n=4/clinical background) to detect CPNE6, VILIP1, and RIPX protein levels in the OB 
across different NDs. OB DPP6 protein levels remains unchanged across all neurodegenerative syndromes (data not shown). (Lower panel) 
Histograms of band densities derived from 41 independent OB samples. Data are presented as mean ± SEM from: Controls (n = 5 cases), 
PSP (n = 10 cases), LBD (n = 10 cases), FTLD (n = 6 cases), and mixed dementia (mix AD VD) (n = 10 cases). *P < 0.05 vs control group; 
** P < 0.01 vs control group; ***P < 0.001 vs control group.
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administered of recombinant human HSP70 in murine 
models of AD has demonstrated dramatic neuroprotective 
effects [48], suggesting that our experimental workflow 
is a useful approach to detect and identify practical 
therapeutic agents for AD treatment. Using data mining-
based methods for proteome-scale PPIs predictions [32], 
we have generated the potential interactome for human 
APP (β-amyloid precursor protein) and Tau proteins 
(Online Resource 8), detecting some OB differentially 
expressed proteins during AD progression as potential 
APP and/or Tau interactors (Online Resource 1 Figure 
5). Although these assumptions should be experimentally 
validated [49, 50], this predictive information may be 
useful to generate new working hypothesis to clarify the 
relationship between both neuropathologic substrates in 
AD.
One of the goals of the present study was to generate 
extensive data on the functional groups of proteins 
involved in the neurodegenerative process that occur in the 
OB during AD pathogenesis. For that, we have undertaken 
a system biology approach performing different molecular 
networks and protein profiling analysis [16, 51, 52] in 
order to identify biologically relevant pathways from 
large-scale OB proteome data. From a functional point 
of view, specific proteomic fingerprints are dynamically 
modulated in a stage-dependent manner throughout 
the OB. In initial stages, the heterogeneous nuclear 
ribonucleoprotein (hnRNP) protein complex was down-
modulated (hnRNPA/B between others) (subnetwork 
A). It has been previously demonstrated that sporadic 
AD entorhinal cortices present a selective loss of hnRNP 
A/B splicing factors leading to the loss of synapses and 
dendrites [53]. Interestingly, hnRNP A1 up-regulation 
induces alternative splicing of the amyloid precursor 
protein (APP) mRNA, which is followed by reduced 
Aβ levels [54], suggesting that a fall of the hnRNP A/B 
protein levels may inversely exacerbate amyloid pathology 
in the OB. 
In intermediate stages, we have detected an 
imbalance in the protein composition of V-type proton 
ATPase (subnetwork B). This multi-subunit protein drives 
the loading of neurotransmitters into synaptic vesicles 
[55], indicating that the cycling of neurotransmitters at 
the olfactory synapse is not totally efficient. Moreover, 
several Collagen VI chains (subnetwork C) and its 
potential interactor AKAP12 are de-regulated in 
intermediate stages, suggesting that modulation of its 
protein levels may be part of the protective mechanisms 
against β-amyloid in olfactory neurons of AD patients 
[31, 33]. 14-3-3 protein family plays a pivotal role in 
Tau phosphorylation [56], and also in oligomerization 
and aggregation [57]. Up-regulation of 14-3-3 members 
have been detected in cortex and choroid plexus of AD 
patients using proteomic technologies [22, 43]. In our 
case, olfactory 14-3-3 proteins (subnetwork D) tend to 
be down-regulated in olfactory neurons in intermediate 
stages. Albeit the brain areas analyzed are different, the 
apparent discrepancy between previous proteomic studies 
and our results may also be due to technological reasons. 
Previous reports have detected over-expression of 14-3-
3 proteins using 2D-electrophoresis. This approach tend 
to detect proteoforms by resolving spots at different 
molecular weight and isoelectric point, hampering the 
analysis of total expression levels of each 14-3-3 isoform. 
However, it can be assumed that protein regulation 
determined by iTRAQ-based approach is more trustworthy 
regarding the overall expression change of a protein as 
they are not influenced by any isoform effects. In parallel, 
a disturbance in a subset of cell adhesion molecules 
(CAMs) and chondroitin sulfate proteoglycans appeared 
in intermediate stages, remaining altered in advanced 
stages (subnetwork E). In general, CAMs participate in 
neuron-neuron adhesion, and triggers signaling pathways 
to axon growth [58]. Specifically, L1CAM binds to 
β-amyloid reducing histopathological hallmarks of AD in 
mice [59], while NCAM1 participates in the maturation of 
the presynaptic endocytic machinery [60]. Furthermore, 
chondroitin sulfate proteoglycans such as neurocan 
(NCAN) and brevican (BCAN) are essential in the 
maintenance of hippocampal long-term potentiation [61, 
62]. In view of these observations, the down-modulation 
of CAM-proteoglycan interactome may contribute to the 
β-amyloid-related synaptic toxicity impairment in the OB 
across intermediate-late phases of AD. 
At the end stage of the disease, an interrupted 
synaptic transmission is largely reflected in the OB. 
There is a generalized inhibition in protein production 
of specific V-type proton ATPase subunits, Adaptor-
related proteins (APs), clathrin heavy chain (CLTC) 
and CAM-proteoglycan complexes (subnetworks 
E and F), suggesting an immature form of synaptic 
vesicle recycling in the OB region [60]. Our proteome-
scale interaction network analysis further revealed an 
impaired mitochondrial function, based on the down-
regulation of subunits of mitochondrial respiratory 
chain complexes I, II, III and V (subnetwork G). This 
impairment is a common finding in human AD brains, and 
also in rodent, and cellular AD models [63, 64], where 
intracellular Aβ accumulation leads to a decrease electron 
transfer efficiency, reduce ATP production, and increase 
ROS production [65]. Overall, our data point out that 
functional protein interactomes and specific pathways 
are dynamically modulated across AD staging in the OB, 
emphasizing the potential impact of stage-dependent 
analysis using high-throughput proteome screenings.
Although the implementation of a pooling strategy 
reduce false-positive rates in proteomic experiments 
and partially control the clinical and pathophysiological 
heterogeneity [34], we further applied complementary 
approaches such as immunohistochemistry and Western 
blotting to analyze in detail the expression of Visinin-
like protein 1 (VILIP1), Dipeptidyl aminopeptidase-
Oncotarget39449www.impactjournals.com/oncotarget
like protein 6 (DPP6), Copine-6 (CPNE6) and RUFY3 
protein (RIPX) in the OB. Both VILIP1 and RIPX are 
up-regulated at the first stages of AD-related pathology, 
when morphological lesions are restricted to the entorhinal 
and transentorhinal cortices. Interestingly, both proteins 
are also maintained in higher levels in advanced stages 
of AD. VILIP1 is a neuronal calcium sensor which 
CSF concentration is usually elevated in AD patients 
compared to control and LBD subjects [25, 26, 66], and 
predicts rates of future cognitive decline in early AD [67]. 
However, the increment in olfactory VILIP1 levels is 
transient, falling in AD subjects with intermediate stages 
in accordance with previous data obtained from cerebral 
cortex of AD patients [68]. It has been proposed that 
the down-regulation of VILIP1 may attenuate neuronal 
signaling pathways regulating the neuroplasticity process, 
contributing to cognitive decline in initial stages of AD 
[69]. In contrast, OB VILIP1 levels were increased in 
FTLD and mixed dementia subjects in our cross-disease 
study. Our data suggest that the complex pattern of up- 
and down-regulation of VILIP1 needs to be studied 
thoroughly in each pathology in order to decipher the 
specific signaling routes involved in VILIP1-dependent 
phosphorylation of Tau [70] and the role of VILIP1 in 
β-amyloid-induced calcium overload [71]. Interestingly, 
calcium sensors also modulate A-type K(+) channels, 
controlling responses to excitatory synaptic inputs [72]. 
DPP6 is an auxiliary subunit of Kv4-mediated A-type 
K(+) channels [27, 73], which deficiency induces a 
decrease in A-type current together with an independent 
reduction in the number of functional excitatory synapses, 
affecting the excitatory synaptic function and dendritic 
branch complexity in murine hippocampus [28, 74]. Our 
data also indicate a specific late reduction in the OB levels 
of DPP6 in AD, suggesting a potential contribution of 
DPP6 in the aberrant synapse stability at the end stage 
of AD-pathology. On the other hand, CPNE6 protein 
levels were only altered in the OB derived from LBD and 
mixed dementia (mix AD VD) indicating that the axon 
maturation process may be differentially compromised 
in the olfactory tract across different NDs [30]. RIPX is 
a poorly characterized protein involved in cytoskeletal 
dynamics in growth cones [75] to control the neuronal 
axon elongation [29]. We have observed a reversed 
olfactory pattern between mixed dementia (Mix AD VD) 
respect to the protein profile observed in AD, indicating 
that RIPX may be considered a common protein mediator 
that plays specific roles in axon guidance across different 
neuropathological backgrounds, compromising the 
regulation of cell polarity and membrane trafficking in 
olfactory neurons [76]. Transcriptional and translational 
events may explain this difference observed in RIPX 
protein levels. A possible explanation is that the vascular 
damage may induce an increment in the RIPX degradation 
rate at mRNA and/or proteins levels at the level of the OB 
in mix AD VD. However, we have to take into account 
that the activation/inhibition of the transcription factor 
machinery that regulate the transcription of RUFY3 
gene may also be compromised (as a consequence of the 
vascular damage), leading to a decrease in RUFY3 mRNA 
and protein levels. However, additional validation studies 
should be conducted employing large cohorts to verify the 
protein expression changes observed in our sample set. 
Although our study has uncovered many intricacies 
in OB protein homeostasis during AD progression, 
there are potential limitations of our study that warrant 
discussion. We have analysed dissected areas that 
contained multiple cell types [77], thus diluting the 
proteomic contribution of each specific cell type. 
Furthermore, the analysis of the OB is not sufficient to 
investigate the full magnitude of proteome modulation 
in AD across the olfactory system. Taking into account 
that neuropathologic substrates also tend to deposit in 
olfactory tract and olfactory cortex, additional proteomic 
studies targeted to these olfactory areas will be necessary 
to complement the proteomic data specifically derived 
from the OB. 
CONCLUSIONS
In summary, we have used a differential proteome-
wide approach revealing stage-dependent molecular 
alterations in the OB during the AD progression. The 
differential proteomes lie in an imbalance in splicing 
factors, interrupted cycling of neurotransmitters, 
alteration in toxic/protective mechanisms of β-amyloid, 
mitochondria-mediated neurodegeneration, and a 
disturbance in neuron-neuron adhesion. Thus, our 
findings provide basic information for understanding 
the implication of the OB in the pathophysiology of 
AD, identifying protein mediators that may be used as 
potential therapeutic agents or even explored in biofluids 
as candidate biomarkers for AD diagnosis and evolution. 
In addition, our study revealed changes in the OB levels 
of specific proteins that had not previously been implied 
in neurological pathogenesis, suggesting that NDs that 
have markedly different clinical and pathological features 




According to the Spanish Law 14/2007 of 
Biomedical Research, inform written consent form of the 
Neurological Tissue Bank of Navarra Health Service was 
obtained for research purposes from relatives of patients 
included in this study. Fifteen AD cases were distributed 
into different groups according to specific consensus 
Oncotarget39450www.impactjournals.com/oncotarget
diagnostic criteria [78-80]: low, intermediate, and high 
neuropathological changes (n = 5/group) (Table 1). Five 
cases from elderly subjects with no history or histological 
findings of any neurological disease were used as a control 
group (Table 1). All brains considered in the discovery 
phase had a post-mortem interval (PMI) lower than 10 
hours (Table 1). For specificity analysis, different NDs 
were considered: Progressive supranuclear palsy (PSP) (n 
= 10 cases; 5F/5M; median age: 74 years), Lewy body 
disease (LBD) (n = 10 cases; 6F/4M; median age: 80 
years), frontotemporal lobar degeneration (FTLD) (n = 6; 
3F/3M; median age: 81 years), mixed dementia (mix AD 
VD) (n = 10 cases; 5F/5M; median age: 85 years), and 
controls (n = 5; 2F/3M; median age: 79 years). 80% of the 
OB samples included in this phase had a PMI lower than 
10 hours (See Online Resource 7). 
Neuropathological study
One hemisphere (usually the left) with the 
corresponding OB was fixed in 10% formalin for 
morphological studies. After fixation (21-25 days), 
representative brain areas from cortical and subcortical 
areas, brainstem, cerebellum and spinal cord were 
taken and embedded in paraffin in order to make 
a neuropathological diagnosis. Neuropathological 
assessment was performed according to standardized 
neuropathological scoring/grading systems, including 
Thal phases of Beta-amyloid deposition, Braak staging 
of neurofibrillary lesions, Consortium to Established a 
Registry for Alzheimer’s Disease, National Institute on 
Aging-Alzheimer’s Association (NIA-AA) guidelines, 
primary age-related tauopathy (PART) criteria, McKeith 
criteria for Lewy body disease, Mackenzie criteria for 
FTLD pathology, NINDS-AIREN criteria for vascular 
dementia, and NINDS criteria for PSP [78-87]. OB beta-
amyloid and Phos-Tau immunostaining were exclusively 
performed in AD and control cases. The OBs were 
embedded in paraffin and 4-μm-thick sagittal sections 
were stained with hematoxylin-eosin and 3-μm-thick 
sagittal sections were processed for immunohistochemical 
analysis. Formalin-fixed sections (3-5 µm-thick) were 
mounted on slides and deparaffinized. After conducting 
a routine antigen retrieval protocol, tissue sections were 
immunohistochemically labelled overnight with a mouse 
monoclonal antibody anti-human PHF-TAU (clone AT-
8, Innogenetics) and a mouse monoclonal (S6F/3D) 
anti Beta-amyloid (Leica). The reaction product was 
visualized using an automated slide immunostainer (Leica 
Bond Max) with Bond Polymer Refine Detection (Leica 
Biosystems Newcastle Ltd). Analysis of OB for specific 
protein deposits aggregates was carried out in a light 
microscope (Olympus BX51) blinded to pathological 
diagnosis. A semiquantitative assessment was performed 
according to Kovacs T et al. [88]. We consider compact 
deposit with central core as mature plaques and granular 
or fibrillar deposit as diffuse plaques. Moreover, Aβ 
immunopositivity was scored on a 4-tiered scale as: 
(-) negative, (+) 1-2 isolated Aβ depositions, (++) 3-4 
Aβ depositions, and (+++) > 4 Aβ depositions. We also 
described different patterns of deposits and its intensity 
for Phos-Tau immunostaining : neurofibrillary tangles, 
neuropil threads and neuritic plaques (n.d: not determined; 
+: low; ++: intermediate; +++ high) (see Table 1). 
All preparations were examined by two independent 
pathologists.
Materials
The following reagents and materials were used: 
anti-GAPDH (Calbiochem), anti-DPP6 (Sigma), anti-
AKAP12, anti-CPNE6, anti-RIPX, anti-VILIP1 (Thermo 
Scientific). Electrophoresis reagents were purchased from 
Biorad and trypsin from Promega.
Immunoblotting analysis
Equal amounts of protein (15 µg) were resolved 
in 12.5% SDS-PAGE gels. OB proteins derived from 
control, AD, PSP, LBD, FTLD, and mix AD VD were 
electrophoretically transferred onto nitrocellulose 
membranes for 45 min at 120 V. Membranes were probed 
with primary antibodies at 1:1000 dilution in 5% nonfat 
milk. After incubation with the appropriate horseradish 
peroxidase-conjugated secondary antibody (1:5000), 
the immunoreactivity was visualized by enhanced 
chemiluminescence (Perkin Elmer). Equal loading of the 
gels was assessed by Ponceau staining and hybridization 
with a GAPDH specific antibody (Calbiochem). Results 
are expressed as an n-fold increase over the values of the 
control group in densitometric arbitrary units.
Immunohistochemistry
For the immunohistochemical study, formalin-
fixed sections (3-5 mm-thick) were mounted on slides 
and deparaffinized. Tissue sections were labelled with the 
following primary antibodies: anti-DPP6 (dilution 1/200), 
anti-AKAP12 (dilution 1/2500), anti-CPNE6 (dilution 
1/500), anti-RIPX (dilution 1/500), anti-VILIP1 (dilution 
1/100). The reaction product was visualized using an 
automated slide immunostainer (Leica Bond Max) with 
Bond Polymer Refine Detection (Leica Biosystems 
Newcastle Ltd).
Sample preparation for proteomic analysis
OB specimens derived from control and AD cases 
(Table 1) were homogenized in lysis buffer containing 7 
M urea, 2 M thiourea, 4% (w/v) CHAPS, 50 mM DTT. 
Oncotarget39451www.impactjournals.com/oncotarget
The homogenates were spinned down at 100.000 x g for 
1 h at 15ºC. Protein concentration was measured in the 
supernatants with the Bradford assay kit (Biorad). Prior 
to proteomic analysis, the individual OB samples were 
grouped into 8 independent pools containing ~ 200 μg 
of protein from 2-3 individual samples each one (see 
experimental design in Online Resource 1-Figure 1).
Protein digestion and peptide iTRAQ labeling
A shotgun comparative proteomic analysis of OB 
proteomes using iTRAQ (isobaric Tags for Relative and 
Absolute Quantitation) was performed [45]. Protein 
extracts were precipitated with methanol/choloroform, 
and pellets dissolved in 7M urea, 2 M thiourea, 4% 
(v/v) CHAPS. Protein quantitation was performed with 
the Bradford assay kit (Bio-Rad). iTRAQ labeling of 
each pooled sample was performed according to the 
manufacturer’s protocol (ABSciex). Briefly, equal 
amounts of OB proteins (80 μg) from each pool were 
reduced with 50 mM tris (2-carboxyethyl) phosphine 
(TCEP) at 60 °C for 1 h. Cysteine residues were alkylated 
with 200 mM methylmethanethiosulfonate (MMTS) at 
room temperature for 15 min. Protein enzymatic cleavage 
was carried out with trypsin (Promega; 1:20, w/w) at 37 
°C for 16 h. Each tryptic digest was labelled according 
to the manufacturer’s instructions with one isobaric 
amine-reactive tags as follows (see Online Resource 
1-Figure 1): Tag113, control group A; Tag114, control 
group B; Tag115, Braak stage I-II group A; Tag116, Braak 
stage I-II group B; Tag117, Braak stage III-IV group 
A; Tag118, Braak stage III-IV group B; Tag119, Braak 
stage V-VI group A; Tag121, Braak stage V-VI group B. 
After 1h incubation, each set of labelled samples were 
independently pooled and evaporated until < 40 μl in a 
vacuum centrifuge. 
Liquid chromatography (LC)
To increase the proteome coverage, the peptide pool 
was injected to an Ettan LC system with a X-Terra RP18 
precolumn (2.1 x 20mm) and a high pH stable X-Terra 
RP18 column (C18; 2.1 mm x 150mm; 3.5μm) (Waters) 
at a flow rate of 40 μl/min. Peptides were eluted with a 
mobile phase B of 5-65% linear gradient over 35 min (A, 
5 mM ammonium bicarbonate in water at pH 9.8; B, 5 
mM ammonium bicarbonate in acetonitrile at pH 9.8). 
14 fractions were collected, evaporated under vacuum 
and reconstituted into 20 μl of 2% acetonitrile, 0.1% 
formic acid, 98% MilliQ-H20 prior to mass spectrometric 
analysis.
Mass spectrometry analysis
Peptides mixtures were separated by reverse phase 
chromatography using an Eksigent nanoLC ultra 2D pump 
fitted with a 75 μm ID column (Eksigent 0.075 x 150). 
Samples were first loaded for desalting and concentration 
into a 0.5 cm length 300 μm ID precolumn packed with the 
same chemistry as the separating column. Mobile phases 
were 100% water 0.1% formic acid (FA) (buffer A) and 
100% Acetonitrile 0.1% FA (buffer B). Column gradient 
was developed in a 70 min two step gradient from 2% B to 
30% B in 60 min and 30%B to 40% B in 10 min. Column 
was equilibrated in 95% B for 5 min and 2% B for 15 min. 
During all process, precolumn was in line with column 
and flow maintained all along the gradient at 300 nl/min. 
Eluting peptides from the column were analyzed using 
an AB Sciex 5600 Triple-TOF system. Information data 
acquisition was acquired upon a survey scan performed in 
a mass range from 350 m/z up to 1250 m/z in a scan time 
of 250 ms. Top 25 peaks were selected for fragmentation. 
Minimum accumulation time for MS/MS was set to 75 
ms giving a total cycle time of 2.1 s. Product ions were 
scanned in a mass range from 100 m/z up to 1500 m/z and 
excluded for further fragmentation during 15 s. 
Data analysis
After MS/MS analysis, data files were processed 
using ProteinPilot™ 4.5 software from AB Sciex 
which uses the algorithm Paragon™ (v.4.0.0.0) [89] for 
database search and Progroup™ for data grouping and 
searched against Uniprot Human database. The search 
parameters allowed for cysteine modification by MMTS 
and biological modifications programmed in the algorithm 
(i.e. phosphorylations, amidations, semitryptic fragments, 
etc.). Reporter ion intensities were bias corrected for the 
overlapping isotope contributions from the iTRAQ tags 
according to the certificate of analysis provided by the 
reagent manufacturer (ABsciex). The peptide and protein 
selection criteria for relative quantitation were performed 
as previously described [90]. Several quantitative 
estimates provided for each protein by ProteinPilot were 
utilized: the fold change ratios of differential expression 
between labelled protein extracts; the p-value, representing 
the probability that the observed ratio is different than 1 
by chance. A decoy database search strategy was also 
used to estimate the false discovery rate (FDR), defined 
as the percentage of decoy proteins identified against the 
total protein identification. The FDR was calculated by 
searching the spectra against the decoy database generated 
from the target database using a non-lineal fitting method 
[91] and displayed results were those reporting a 1% 
Global FDR or better. The results were then exported into 
Excel for manual data interpretation. Although relative 
quantification and statistical analysis were provided by the 
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ProteinPilot software, an additional 1.3-fold change cutoff 
for all iTRAQ ratios (ratio ≤0.77 or ≥1.3) was selected to 
classify proteins as up- or down-regulated. Proteins with 
iTRAQ ratios below the low range (0.77) were considered 
to be underexpressed, whereas those above the high range 
(1.3) were considered to be overexpressed. 
Bioinformatic analysis
The proteomic information was analyzed using 
bioinformatic tools including DAVID (Database for 
Annotation, Visualization and Integrated Discovery) 
Bioinformatics Resources (v6.7), Panther, and Reactome 
tools [52, 92]. These programs detect and infer 
differentially activated/deactivated pathways as a result 
of AD phenotypes. The identification of specifically 
dysregulated regulatory/metabolic networks during the AD 
progression was analysed by STRING (Search Tool for 
the Retrieval of Interacting Genes) software (v.9.1) (http://
stringdb.org/) [51]. This database includes interactions 
from published literature describing experimentally 
studied interactions, as well as those from genome analysis 
using several well-established methods based on domain 
fusion, phylogenetic profiling and gene neighbourhood 
concepts. A higher score was assigned when an association 
is supported by several types of evidence. To minimize 
false positives as well as false negatives, all interactions 
tagged as “low-confidence” ( < 0.4) in STRING database 
have been eliminated from this study.
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